← Browse by Condition
Medical Condition
central nervous system lymphoma
Total Trials
5
Recruiting Now
5
Trial Phases
Phase 2, Phase 1, Phase 1, Phase 2
Lymphoma trials span diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, Hodgkin lymphoma, mantle cell lymphoma, and T-cell lymphomas β€” each with distinct biology and treatment response. CAR-T cell therapy has established a new standard in relapsed/refractory DLBCL, and trials now aim to move this approach earlier in the treatment sequence.
Active trials evaluate bispecific antibodies (mosunetuzumab, epcoritamab, glofitamab), next-generation CAR-T cell products (CD19/CD22 dual targets, BCMA-targeting), BTK inhibitors in B-cell lymphomas, and total metabolic volume on PET as a predictive biomarker for treatment adaptation.
Frequently Asked Questions — central nervous system lymphoma Clinical Trials
How many clinical trials are currently recruiting for central nervous system lymphoma?
ClinicalMetric currently tracks 5 actively recruiting clinical trials for central nervous system lymphoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 5. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for central nervous system lymphoma?
central nervous system lymphoma research spans Phase 1 (2 trials), Phase 2 (3 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a central nervous system lymphoma clinical trial?
Eligibility criteria for central nervous system lymphoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1 2
Phase 2 3
Top Sponsors
1 trial
1 trial
1 trial
1 trial
1 trial
Recruiting Clinical Trials
NCT04792489 Phase 2
Recruiting
Enrollment
315 pts
Location
United States, Canad...
Sponsor
Miltenyi Biomedicine GmbH
NCT07082868 Phase 1
Recruiting
Enrollment
26 pts
Location
United States
Sponsor
Memorial Sloan Kettering Cance...
NCT05011045
Recruiting
Enrollment
100 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
NCT04186520 Phase 1, Phase 2
Recruiting
Enrollment
100 pts
Location
United States
Sponsor
Medical College of Wisconsin
NCT07416890 Phase 2
Recruiting
Enrollment
24 pts
Location
China
Sponsor
Zhejiang Cancer Hospital
Related Conditions
mantle cell lymphoma mcl (2) secondary central nervous system lymphoma (2) refractory diffuse large b cell lymphoma dlbcl (1) relapsed diffuse large b cell lymphoma (1) high grade b cell lymphoma hgbcl (1) primary mediastinal b cell lymphoma pmbcl (1) transformed lymphoma (1) richter transformation (1) transplant ineligible 2nd line dlbcl (1) primary central nervous system lymphoma pcnsl (1) primary central nervous system lymphoma (1) relapsed primary central nervous system lymphoma (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology